Augmenix Secures $15,000,000 New Financing Round

  • Feed Type
  • Date
    5/12/2011
  • Company Name
    Augmenix
  • Mailing Address
    204 2nd Avenue Waltham, MA 02451
  • Company Description
    Augmenix, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers.
  • Website
    http://www.augmenix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The agreement also provides Varian with the exclusive option to acquire the rest of Augmenix provided certain agreed-upon milestones have been met.
  • M&A Terms
  • Venture Investor
    Varian Medical Systems

By posting a comment, you agree to our terms and conditions.